Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-14
2006-11-14
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S394000
Reexamination Certificate
active
07135490
ABSTRACT:
A treatment for glomerulonephritis is disclosed comprising administering (±)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1 -[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate.
REFERENCES:
patent: 5128356 (1992-07-01), Naka et al.
patent: 5162326 (1992-11-01), Naka et al.
patent: 5183899 (1993-02-01), Naka et al.
patent: 5196444 (1993-03-01), Naka et al.
patent: 5250554 (1993-10-01), Naka et al.
patent: 5284661 (1994-02-01), Morimoto et al.
patent: 5719173 (1998-02-01), Nishikawa et al.
patent: 5889036 (1999-03-01), Nishikawa et al.
patent: 6319938 (2001-11-01), Nishikawa et al.
patent: 0 392 317 (1990-10-01), None
patent: 0 400 835 (1990-12-01), None
patent: 0 591 136 (1991-03-01), None
patent: 0 425 921 (1991-05-01), None
patent: 0 430 300 (1991-06-01), None
patent: 0 434 038 (1991-06-01), None
patent: 0 445 811 (1991-09-01), None
patent: 0 461 039 (1991-11-01), None
patent: 0 483 683 (1992-05-01), None
patent: 0 518 033 (1992-12-01), None
patent: 0 520 423 (1992-12-01), None
patent: 0 588 299 (1994-03-01), None
patent: 0 603 712 (1994-06-01), None
patent: WO 92/00067 (1992-01-01), None
patent: WO 92/04343 (1992-03-01), None
patent: WO 92/10182 (1992-06-01), None
Cattell, “Macrophages in acute glomerular inflammation,”Kidney Int.,1994, pp. 945-952, vol. 45, © International Society of Nephrology, London, England.
El Nahas, “Growth factors and glomerular sclerosis,”Kidney Int.,1992, pp. S15-S20, vol. 41, Suppl. 36© International Society of Nephrology, Sheffield, United Kingdom.
Okuda et al., “Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis,”J. Clin. Invest.,Aug. 1990, pp. 453-462, vol. 86, © The American Society for Clinical Investigation, Inc., USA.
Couser, “Pathogenesis of glomerulonephritis,”Kidney Int.,1993, pp. S19-S26, vol. 44, Suppl. 42, © International Society of Nephrology, Seattle, Washington, USA.
Zatz et al., “Pathogenesis of Diabetic Microangiopathy, The Hemodynamic View,”Am. J. Med.,Mar. 1986, pp. 443-453, vol. 80, USA.
Moustonen et al., “The nephrotic syndrome in lgA glomerulonephritis, response to corticosteroid therapy,”Clin. Nephrol.,1983, p. 172, vol. 20, No. 4.
Sato et al., “Clinical and histological characteristics of patients with lgA nephropathy showing massive proteinuria,”Jp. Nephrol.,1986, p. 1179, vol. 28, No. 9.
Lai et al., “Corticosteroid therapy in lgA nephropathy with nephrotic syndrome: a long-term controlled trial,”Clin. Neph.,1986, pp. 174-180, vol. 26, No. 4.
Balow et al., “Effect of treatment on the evolution of renal abnormalities in lupus nephritis,”New Engl. J. Med.,Aug. 23, 1984, p. 491, vol. 311, No. 8, USA.
Brazy et al., “Progression of renal insufficiency; role of blood pressure,”Kidney Int.,1989, pp. 670-674, vol. 35, © International Society of Nephrology, USA.
Raij, “Role in hypertension in progressive glomerular injury in glomerulonephritis,”Hypertension,1986, pp. 30-33, vol. 8, Suppl. I.
Copper et al., “Nephropathy in Model Combining Genetic Hypertension with Experimental Diabetes, Enalapril Versus Hydralazine and Metoprolol Therapy,”Diabetes,Dec. 1990, pp. 1575-1579, vol. 39.
Ferder et al., “Angiotensin Converting Enzyme Inhibitors Versus Calcium Antagonists in the Treatment of Diabetic Hypertensive Patients,”Hypertension,Feb. 1992, pp. II-237-II-242, vol. 19, No. 2, Supp. II, Argentina.
Wolf et al., “Angiotensin II Stimulates the Proliferation and Biosynthesis of Type I Collagen in Cultured Murine Mesangial Cells,”Am. J. Path.,Jan. 1992, pp. 95-107, vol. 140, No. 1, © American Association of Pathologists, USA.
Anderson et al., “Angiotensin II causes mesangial cell hypertrophy,”Hypertension,1993, pp. 29-35, vol. 21.
Reddi et al., “Enalapril Improves Albuminuria by Preventing Glomerular Loss of Heparan Sulfate in Diabetic Rats,”Biochem. Med.&Met. Bio.,1991, pp. 119-131, vol. 45, © Academic Press, Inc.
Morrelli et al., “Effects of Converting-Enzyme Inhibition on Barrier Function in Diabetic Glomerulopathy,”Diabetes,Jan. 1990, pp. 76-82, vol. 39.
Klein et al., “Glomerular Proteoglycans in Diabetes, Partial Structural Characterization and Metabolism of De Novo Synthesized Heparan-35SO4and Dermatan-35SO4Proteoglycans in Streptozocin-Induced Diabetic Rats,”Diabetes,Oct. 1986, p. 1130, vol. 35.
Bohm et al., “The Angiotensin II Antagonist BIBR277 Normalized Blood Pressure and Improves . . . ,”The FASEB Jnl.7(3):A246 (1993).
Dunn, “Prostaglandins, Angiotensin II, and Proteinuria,”Nephron,5:30-37 (1990).
Honma et al., “Renal protective effects of the angiotensin II (Ang II) receptor antagonist CV-11974 . . . ,”JANS4:513 (1993).
Kohara et al., “Angiotensin Blockade and the Progression of Renal Damage in the Spontaenously Hypertensive Rat,”Hypertension21(6):975-979 (1993).
MacKenzie et al.,Journal of the American Society of Nephrology4(3):775 (abstract).
Noda et al., “Inhibition of Rabbit Aortic Angiotensin II (AII) Receptor by CV-11974, A New Nonpeptide All Antagonist,”Bio. Pharm.46(2):311-318 (1993).
Shibouta et al.,Japanese Pharmacology and Therapeutics,21(5):227-235 (abstract) 1993.
Wolf et al., “Glucose-Induced Hypertrophy in Cultured Proximal Tubule Cells: Enhancement by Angiotensin II (AII),”The FASEB Jnl.5(5):A1039 (1991).
Lafayette et al., “Journal of Clinical Investigation”, vol. 90, No. 3, pp. 766-771 (1992).
Amuchastegui et al., Journal of the American Society Nephrology, vol. 3, No. 3, p. 754 (1992).
Kubo Keiji
Nishikawa Kohei
Shibouta Yumiko
Foley & Lardner LLP
Spivack Phyllis G.
Takeda Pharmaceutical Company Limited
LandOfFree
Method for the treatment of glomerulonephritis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the treatment of glomerulonephritis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the treatment of glomerulonephritis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3622435